Cancer Immunol Res. 2025 Oct 20. doi: 10.1158/2326-6066.CIR-24-0207. Online ahead of print. ABSTRACT Aberrant expression of the oncogene SALL4 is associated with stemness, more aggressive cancer phenotype, and reduced patient survival in various tumor types making SALL4 a potential target for cancer immunotherapy. We conducted a transcriptional analysis of SALL4 expression in colorectal cancer (CRC) … Read more
Cancer Immunol Res. 2025 Oct 20. doi: 10.1158/2326-6066.CIR-25-0433. Online ahead of print. ABSTRACT Immune checkpoint blockade (ICB) has transformed colorectal cancers (CRCs) therapy, yet the majority of microsatellite-stable (MSS) CRCs remain refractory due to insufficient tumor-immune cell crosstalk. Identifying molecular regulators that modulate the tumor immune microenvironment (TIME) is crucial for expanding ICB efficacy. Here, … Read more
Cancer Immunol Res. 2025 Oct 13. doi: 10.1158/2326-6066.CIR-25-0203. Online ahead of print. ABSTRACT Neoantigen-specific T cells recognize tumor cells and are critical for cancer immunotherapies to be effective. However, the transcriptional program controlling the cell-fate decisions by neoantigen-specific T cells is incompletely understood. Here, using joint single-cell transcriptome and T-cell receptor (TCR) profiling, we mapped … Read more
Cancer Immunol Res. 2025 Oct 13. doi: 10.1158/2326-6066.CIR-24-1259. Online ahead of print. ABSTRACT Natural killer (NK) cells play a critical role in anti-cancer immunity through their direct cytotoxicity and production of cytokines, such as Flt3L. NK cell production of Flt3L controls conventional type I dendritic cell (cDC1) abundance in the tumor and promotes protective immune … Read more
Cancer Immunol Res. 2025 Oct 8:OF1-OF2. doi: 10.1158/2326-6066.CIR-25-1097. Online ahead of print. ABSTRACT Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and … Read more
Cancer Immunol Res. 2025 Oct 1. doi: 10.1158/2326-6066.CIR-25-0343. Online ahead of print. ABSTRACT Immune check-point blockade for the treatment of malignancies has been focused on reversing inhibitory pathways in T lymphocytes. Natural killer (NK) cells are a potent innate defense against tumors and virally infected cells, but their therapeutic manipulation for anti-cancer immunity has been … Read more
Cancer Immunol Res. 2025 Oct 1;13(10):1509. doi: 10.1158/2326-6066.CIR-13-10-WWR. NO ABSTRACT PMID:41030051 | DOI:10.1158/2326-6066.CIR-13-10-WWR
Cancer Immunol Res. 2025 Sep 30. doi: 10.1158/2326-6066.CIR-24-1342. Online ahead of print. ABSTRACT Low or absent expression of major histocompatibility complex (MHC) on tumor cells is a presumed mechanism of resistance to immunotherapy, but evidence for this has largely been indirect. Likewise, whether immunotherapy can be effective without tumor MHC expression is also poorly understood. … Read more
Cancer Immunol Res. 2025 Sep 26. doi: 10.1158/2326-6066.CIR-25-0182. Online ahead of print. ABSTRACT Current histopathological classifications do not reliably distinguish patients with primary cutaneous squamous cell carcinoma (cSCC) at risk of relapse from those with non-relapsing tumors. This underscores the need for molecular signatures capable of stratifying patients during primary tumor resection. Here, we used … Read more
Cancer Immunol Res. 2025 Sep 26. doi: 10.1158/2326-6066.CIR-24-1083. Online ahead of print. ABSTRACT Despite advances in cancer immunotherapy, treatment response is still highly variable. One contributing factor is the tumor microenvironment and specifically the presence of suppressive immune cells such as regulatory T (Treg) cells. Being able to target these specifically, whilst leaving effector T … Read more
